SRF7 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
Based on analysis of available research (primarily focused on IRF7 antibodies due to limited peer-reviewed data on "SRF7" nomenclature in published literature), here is a structured FAQ addressing key scientific considerations:
Advanced Research Questions
3. Designing longitudinal cohort studies for IRF7 autoantibody profiling
Key methodological considerations:
-
Sampling: 3-phase collection (baseline, flare, remission) with matched PBMCs
-
Analysis: Multiplexed autoantibody arrays (≥50 antigens) + IFN-α serum quantification
-
Statistical power: Require n=387 patients to detect OR=0.8 at 80% power (α=0.05) based on meta-analysis
4. Mechanistic studies of IRF7 variants in autoantibody production
Experimental workflow for rs1131665 functional analysis:
-
CRISPR-edited Jurkat T-cells (C/G genotypes)
-
Dual-luciferase reporter assay with IFN-β promoter
-
Chromatin accessibility profiling (ATAC-seq)
-
B cell co-culture with autologous Tfh cells
Cross-disease comparative analysis of IRF7 epitopes
Methodological Considerations Table
| Challenge | Solution | Key Parameters |
|---|---|---|
| Low-titer antibodies | Immunodepletion + signal amplification | Limit of detection: 0.1 ng/mL |
| Epitope spreading | Longitudinal epitope mapping | 6-month intervals over 3 years |
| Cross-reactivity | Structural modeling (PyMOL) | <5% homology to IRF3/5 |
Data from genome-wide association studies (GWAS) demonstrate:
